By Diagnostics World Staff
June 6, 2017 | Interpace announced that the company has entered into a Laboratory Services Agreement with Einstein Medical Center of Philadelphia (Einstein) to provide expanded laboratory analytical services to Einstein for improved identification of indeterminate thyroid nodules, through Interpace's combined ThyGenX and ThyraMIR molecular tests.
The new Agreement provides access for Einstein’s Endocrinologists, Ear Nose and Throat physicians, and Otolaryngologists to Interpace’s products for thyroid nodules that are initially deemed indeterminate. Nationwide, approximately 20% of thyroid nodules assessed using fine needle aspirate (FNA) biopsies are indeterminate and eligible for further analysis with molecular testing. The American Thyroid Association (ATA) has published guidelines that support the use of molecular testing in those circumstances where traditional cytopathology is indeterminate and unable to differentiate between malignant and benign thyroid nodules.
Einstein Medical Center of Philadelphia is associated with Einstein Healthcare Network, a private, not-for-profit organization with several major facilities and many outpatient centers. Einstein has provided healthcare services for nearly 150 years in the greater Philadelphia region and their primary mission is to provide compassionate, high-quality healthcare to the greater Philadelphia region. Many of the patients their specialists serve are referred by other institutions due to Einstein’s expertise in the area of diagnosing and treating thyroid cancer.